Additionally, Ron Geller and his team reported that Hsp90 inhibitors may present attractive antiviral therapeutics for the treatment of RSV (Respiratory syncytial virus) infections [159] as Hsp90 inhibitors degrade the viral protein during infection, and this shows the potential of chaperone inhibitors as antivirals exhibiting high barriers to the development of drug resistance during such viral infections. The gene discussed is HSP90AA1; the disease is infection.